Clinical trials
Bone Cancer Metastatic clinical trials
Below are recruiting bone cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06752811RecruitingPhase 3
Testing a new paclitaxel formula for advanced pancreatic cancer
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Nanjing, JiangsuAges 18–75 - NCT06611891RecruitingPhase 3
PET scan study for breast cancer with hormone receptors
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
GrenobleAges 18–99 - NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT03401294RecruitingPhase 2
Turn unresectable liver cancer into operable colorectal cancer
This Phase 2 study tests a treatment strategy to shrink or control colorectal cancer that has spread only to the liver, with the goal of making it removable by surgery. If you qualify, it may offer a chance to move from “not operable” to “operable,” but it’s still experimental.
Regina, SaskatchewanAges 18–70 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT06143553RecruitingPhase 3
Paclitaxel micelles for metastatic breast cancer
This trial tests a new form of paclitaxel (a chemotherapy drug) for metastatic breast cancer that is HER2-negative. It may be an option if your cancer has returned or not improved after 2 to 4 previous treatments.
Nanjing, JiangsuAges 18 years+ - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT06341296RecruitingPhase 2
Irinotecan liposomes for first-line advanced colorectal cancer
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Sichuan, Sichuan, ChengduAges 18–85 - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT05413421RecruitingPhase 1
ORIC-944 for metastatic prostate cancer after hormone therapy
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Colorado Springs, ColoradoAges 18 years+ - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70 - NCT06825624RecruitingPhase 1
Testing HS-20093 combinations for advanced colorectal cancer
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06887218RecruitingPhase 2
Testing a new combination for advanced colorectal cancer
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Fayetteville, ArkansasAges 18–130 - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+
Hear when a new Bone Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone cancer metastatic?
- Yes. Clin2 currently lists 741 recruiting bone cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.